有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Olmesartan medoxomil;CS-866DM;CS-866;Olmetec;Benicar;Benevas
Chemical Name 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[2-(1H-5-tetrazolyl)biphenyl-4-ylmethyl]imidazole-5-carboxylic acid 5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester
CAS 144689-63-4
Related CAS
Formula C29H30N6O6
Structure
Formula Weight 558.59905
Stage 上市-2002
Company Sankyo (Originator), Forest (Marketer), Pfizer (Marketer), Menarini (Comarketer), Nikken Chemicals (Comarketer), Sanwa (Comarketer), Kowa (Codevelopment)
Activity/Mechanism CARDIOVASCULAR DRUGS, Diabetic Nephropathy, Agents for, ENDOCRINE DRUGS, Hypertension, Treatment of, Treatment of Diabetic Complications, Angiotensin AT1 Antagonists
Syn. Route 3
Route 1
the cyclization of trimethyl orthobutyrate (i) with (z)-2,3-diaminobutenedinitrile (ii) gives 2-propylimidazole-4,5-dicarbonitrile (iii), which is hydrolyzed with 6n hcl to the corresponding dicarboxylic acid (iv). the esterification of (iv) with ethanol/dry hcl yields the diethyl ester (v), which is treated with methylmagnesium iodide in ethyl ether/dichloromethane affording 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylic acid ethyl ester (vi). the condensation of (vi) with 5-[4-(bromomethyl)biphenyl-2-yl]-1-(triphenylmethyl)tetrazole (vii) by means of potassium tert-butoxide in dimethylacetamide (dma) (1) or sodium hydride in dmf (2) gives 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2-[1-(triphenylmethyl)-5-tetrazolyl]biphenyl-4-ylmethyl]imidazole-5-carboxylic acid ethyl ester (viii), which is hydrolyzed with lioh in dioxane/water to the corresponding free acid (ix). the esterification of (ix) with the chloromethyldioxole (x) by means of k2co3 in dma gives the desired ester (xi), which is finally deprotected with aqueous acetic acid.
List of intermediates No.
n-isopropyl-n-phenylamine (vii)
(e)-3-(3-pyridinyl)-2-propenoic acid (i)
(e)-3-(3-pyridinyl)-2-propenoyl chloride (ii)
1-(trimethylsilyl)-2-pyrrolidinone (iii)
(4r)-3-[(2s,3s)-3-amino-2-hydroxy-4-phenylbutanoyl]-n-(tert-butyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide (iv)
3,3-dimethyldihydro-2,5-furandione (v)
4-[((1s,2s)-1-benzyl-3-[(4r)-4-[(tert-butylamino)carbonyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl)amino]-2,2-dimethyl-4-oxobutyric acid (vi)
4-([(2s,3s,5r)-3-azido-5-[5-methyl-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl]methoxy)-2,3-dimethyl-4-oxobutyric acid (viii)
4-amino-5-chloro-2-methoxybenzoic acid methoxycarbonyl anhydride (ix)
butyl 2-bromoacetate (x)
2-hydroxy-5-methoxybenzaldehyde (xi)
Reference 1:
    graul, a.; leeson, p.; casta?er, j.; cs-866. drugs fut 1997, 22, 11, 1205.
Reference 2:
    yanagisawa, h.; shimoji, y.; fujimoto, k.; kanazaki, t.; anemiya, y.; koike, h.; sada, t. (sankyo co., ltd.); angiotensin ii antagonist 1-biphenylmethylimidazole cpds. and their therapeutic use. ep 0503785; ep 0545912; jp 1993078328; us 5616599 .

Route 2
2) the hydrolysis of 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylic acid ethyl ester (vi) with lioh in water gives the corresponding free acid (xii), which is esterified with the chloromethyldioxole (x) by means of diisopropylethylamine (diea) yielding the expected ester (xiii). finally, this compound is condensed with 5-[4-(bromomethyl)biphenyl-2-yl]-1-(triphenylmethyl)tetrazole (vii) by means of potassium carbonate in dma to afford the protected cs-866 (xi) already obtained.
List of intermediates No.
n-isopropyl-n-phenylamine (vii)
4-[((1s,2s)-1-benzyl-3-[(4r)-4-[(tert-butylamino)carbonyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl)amino]-2,2-dimethyl-4-oxobutyric acid (vi)
butyl 2-bromoacetate (x)
2-hydroxy-5-methoxybenzaldehyde (xi)
3-bromo-2-hydroxy-5-methoxybenzaldehyde (xii)
4-(7-bromo-5-methoxy-1-benzofuran-2-yl)pyridine (xiii)
Reference 1:
    graul, a.; leeson, p.; casta?er, j.; cs-866. drugs fut 1997, 22, 11, 1205.
Reference 2:
    yanagisawa, h.; shimoji, y.; fujimoto, k.; kanazaki, t.; anemiya, y.; koike, h.; sada, t. (sankyo co., ltd.); angiotensin ii antagonist 1-biphenylmethylimidazole cpds. and their therapeutic use. ep 0503785; ep 0545912; jp 1993078328; us 5616599 .

Route 3
3) the amidation of 4-methylbiphenyl-2-carboxylic acid (xiv) with tert-butylamine by means of oxalyl chloride in dichloromethane gives the corresponding tert-butylamide (xv), which is brominated with n-bromosuccinimide (nbs) and benzoyl peroxide in ccl4 yielding 4-(bromomethyl)-n-(tert-butyl)biphenyl-2-carboxamide (xvi). the condensation of (xvi) with 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylic acid ethyl ester (vi) by means of potassium tert-butoxide in dma affords 1-[2-(n-tert-butylcarbamoyl)biphenyl-4-ylmethyl]-4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylic acid ethyl ester (xvii), which by reaction with oxalyl chloride in dichloromethane is converted into 1-(2-cyanobiphenyl-4-ylmethyl)-4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylic acid ethyl ester (xviii). the cyclization of (xviii) with tributyltin azide in toluene gives 4-(1-hydroxy-1-methylethyl)-2-propyl 1-[2-(5-tetrazolyl)biphenyl-4-ylmethyl]imidazole-5-carboxylic acid ethyl ester (xix), which is finally tritiated with trityl chloride in pyridine to afford 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2-[1-(triphenylmethyl)-5-tetrazolyl]biphenyl-4-ylmethyl]imidazole-5-carboxylic acid ethyl ester (viii), already obtained.
List of intermediates No.
4-[((1s,2s)-1-benzyl-3-[(4r)-4-[(tert-butylamino)carbonyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-2-hydroxy-3-oxopropyl)amino]-2,2-dimethyl-4-oxobutyric acid (vi)
4-([(2s,3s,5r)-3-azido-5-[5-methyl-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]tetrahydro-2-furanyl]methoxy)-2,3-dimethyl-4-oxobutyric acid (viii)
4-(7-bromo-5-methoxy-1-benzofuran-2-yl)-1-methylpyridinium (sulfonatooxy)methane (xiv)
4-(7-bromo-5-methoxy-1-benzofuran-2-yl)-1-methyl-1,2,3,6-tetrahydropyridine (xv)
4-(7-bromo-5-methoxy-1-benzofuran-2-yl)-1-methylpiperidine (xvi)
ethyl 4-(7-bromo-5-methoxy-1-benzofuran-2-yl)-1-piperidinecarboxylate (xvii)
1-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1h-pyrazol-3-amine (xviii)
1-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1h-pyrazol-3-ylformamide (xix)
Reference 1:
    mizuno, m.; sada, t.; ikeda, m.; fukuda, n.; miyamoto, m.; yanagisawa, h.; koike, h.; pharmacology of cs-866, a novel nonpeptide angiotensin ii receptor antagonist. eur j pharmacol 1992, 285, 181-188.
Reference 2:
    graul, a.; leeson, p.; casta?er, j.; cs-866. drugs fut 1997, 22, 11, 1205.

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名奥美沙坦酯;英文名Olmesartan medoxomil;CS-866DM;CS-866;Olmetec;Benicar;Benevas;CAS[144689-63-4]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
北京富安凯科技有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
呋虫胺和烯啶虫胺继续扩作
华南地区环氧丙烷市场稳定
华东地区丁二烯市场盘整
苯胺跌势难改
醋酸市场供需平衡
丙炔氟草胺领军“其他PPO抑制
华北地区醋酸价格整体上调
山东地区环氧丙烷市场稳定
吡丙醚和氟啶虫酰胺继续扩作
损失或超6千万!这家上市公司被
嘧菌胺获欧盟批准开展再评审,但
丰山集团正式挂牌,发行首日秒封
PTA 回调为主
新型“超分子纳米囊”可减少农药
红太阳子公司南京生化完成增资工
装置集中检修 丁酮强势上涨难持
关于农药登记有关行政许可办理系
东北地区甲苯行情暂稳
新增一家毒氟磷制剂登记企业
华中地区甲苯行情暂稳
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明